Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 2,940 Shares

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 2,940 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares of the company’s stock, valued at approximately $965,531.49. This represents a 13.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Robert Chess also recently made the following trade(s):

• On Tuesday, January 7th, Robert Chess sold 5,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00.
• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total transaction of $181,682.40.

Twist Bioscience Stock Performance

Shares of TWST stock traded down $2.43 during trading hours on Tuesday, hitting $46.20. The company’s stock had a trading volume of 1,012,959 shares, compared to its average volume of 834,298. The company has a 50 day moving average of $48.87 and a 200 day moving average of $46.07. The stock has a market cap of $2.76 billion, a PE ratio of -13.67 and a beta of 1.87. The company has a current ratio of 4.96, a quick ratio of 4.54 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the firm earned ($0.75) EPS. The business’s revenue for the quarter was up 24.1% on a year-over-year basis. On average, sell-side analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

TWST has been the topic of a number of analyst reports. Barclays cut their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Scotiabank lifted their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.80.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently made changes to their positions in the company. EntryPoint Capital LLC acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $420,000. Vanguard Group Inc. raised its position in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after acquiring an additional 189,791 shares during the period. Fox Run Management L.L.C. raised its position in Twist Bioscience by 57.9% during the fourth quarter. Fox Run Management L.L.C. now owns 16,739 shares of the company’s stock worth $778,000 after acquiring an additional 6,138 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Twist Bioscience during the fourth quarter worth $562,000. Finally, Hillsdale Investment Management Inc. raised its position in Twist Bioscience by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock worth $3,625,000 after acquiring an additional 300 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.